Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug containing three active ingredients: lidocaine, osmic acid, and prednisolone. Lidocaine is a local anesthetic that blocks sodium channels in neurons to prevent pain signal transmission[1]. Prednisolone is a synthetic corticosteroid with anti-inflammatory and immunosuppressive effects, acting by binding to the glucocorticoid receptor and modulating gene expression[3]. Osmic acid (osmium tetroxide) is not commonly used as a pharmaceutical agent but has been historically used for its sclerosing properties in certain medical procedures; however, it is not typically included in standard pharmaceutical combinations for pain or inflammation. The combination of these agents would theoretically provide both local anesthesia (lidocaine) and anti-inflammatory action (prednisolone), with possible additional tissue effects from osmic acid.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + osmic acid + prednisolone.